GlassScriptPhysician profile
Howard A Lippes
NPI 1750343141
$139,036.37
in general payments reported to CMS, 2019-2025
64 companies · $3,675 in 2025
The $3,675 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $23K · 2021: $29K · 2022: $27K · 2023: $11K · 2024: $3,139 · 2025: $3,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,244 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,271.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,243.75 |
| Education | $114.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $81,279.74 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,561.30 | 2019-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $8,956.50 | 2019-2025 | Freestyle Libre 3, Eterna |
| Dexcom, INC. | $8,749.67 | 2019-2024 | Dexcom G6 Transmitter |
| Mannkind Corporation | $7,523.50 | 2019-2025 | Afrezza |
| Janssen Pharmaceuticals, INC | $5,826.11 | 2019-2021 | |
| Lilly USA, LLC | $4,800.70 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,492.64 | 2019-2025 | Tepezza, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $1,175.94 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $846.19 | 2019-2025 | Lokelma, Farxiga, Airsupra |
| Abbvie INC. | $704.86 | 2019-2025 | |
| Insulet Corporation | $594.96 | 2019-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $590.30 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $496.13 | 2020-2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $484.76 | 2019-2025 | Unithroid |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $415.76 | 2019-2025 | Korlym |
| Pfizer INC. | $402.12 | 2019-2025 | |
| Amarin Pharma, INC. | $302.04 | 2019-2022 | |
| Horizon Therapeutics Plc | $300.40 | 2021-2023 | Tepezza |
| Radius Health, INC. | $297.11 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $275.15 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Ascensia Diabetes Care US INC. | $249.07 | 2021-2024 | |
| Ascendis Pharma Endocrinology INC | $236.35 | 2024-2025 | Yorvipath |
| Novartis Pharmaceuticals Corporation | $207.64 | 2022-2025 | |
| Recordati_rare_diseases_inc. | $199.96 | 2021-2025 | Isturisa, Signifor Lar |
| Medtronic, INC. | $164.65 | 2021-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $139.08 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Amphastar Pharmaceuticals, INC. | $136.73 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $122.13 | 2022-2025 | |
| Beta Bionics, INC. | $109.26 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Valeritas, INC. | $96.23 | 2019 | |
| Chiesi USA, INC. | $86.82 | 2024-2025 | Mycapssa, Myalept |
| Neurocrine Biosciences, INC. | $80.26 | 2025 | |
| Ibsa Pharma INC. | $74.30 | 2021-2025 | Flector, Tirosint, Licart |
| Sequel Med Tech, LLC | $70.69 | 2025 | Twiist |
| Almatica Pharma LLC | $65.23 | 2024-2025 | Teriparatide |
| Ipsen Biopharmaceuticals, INC | $63.70 | 2019-2020 | |
| Amryt Pharma Holdings LTD | $63.55 | 2022-2023 | Mycapssa |
| Kyowa Kirin, INC. | $55.35 | 2024-2025 | Crysvita |
| Zealand Pharma US, INC. | $52.90 | 2021-2022 | |
| Gilead Sciences, INC. | $50.56 | 2025 | |
| Senseonics, Incorporated | $47.00 | 2019 | |
| Daiichi Sankyo INC. | $45.57 | 2022-2023 | Injectafer |
| Clarus Therapeutics INC. | $45.51 | 2021 | |
| Exact Sciences Corporation | $43.26 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $42.18 | 2023 | Arexvy, Shingrix |
| Nestle Healthcare Nutrition INC. | $35.05 | 2022 | |
| Lifescan, INC. | $34.16 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $33.35 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.64 | 2022 | |
| Optinose US, INC. | $29.48 | 2024-2025 | |
| Esperion Therapeutics, INC. | $27.60 | 2023-2024 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $25.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.86 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $24.45 | 2025 | Imcivree |
| Mirum Pharmaceuticals, INC. | $22.62 | 2025 | Cholbam, Ctexli |
| Eusa Pharma (US) LLC | $22.48 | 2022 | |
| Eisai INC. | $17.86 | 2020 | |
| Zyla Life Sciences, INC. | $15.53 | 2020 | |
| Allergan, INC. | $14.77 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $14.05 | 2025 | Neffy |
| Medtronic Minimed, INC. | $13.62 | 2020 | |
| Antares Pharma, INC. | $13.45 | 2019 | |
| Cequr Corporation | $11.85 | 2023-2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Lippes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.